The median age of patients in the trial was 77 years (range 68-87 years) of which 67% had intermediate-risk cytogenetics and 33% had unfavorable cytogenetics. Importantly, the complete response rate at the dose level which the Company intends to progress into the Phase 2 trial was 50% in patients with low peripheral blast (PB) burden. Most serious adverse events (SAEs) were infections and cytopenias that are considered to be consequences of AML and not drug related.
Catalyst
Slingshot members are tracking this event:
Actinium Pharmaceuticals Announces Positive Safety and Efficacy Results From Phase 1 Actimab-A Trial in Patients With Newly Diagnosed Acute Myeloid Leukemia and Provides Guidance on Plans for Phase 2 Clinical Trial
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ATNM |
|
|
||||
Additional Information
The median age of patients in the trial was 77 years (range 68-87 years) of which 67% had intermediate-risk cytogenetics and 33% had unfavorable cytogenetics. Importantly, the complete response rate at the dose level which the Company intends to progress into the Phase 2 trial was 50% in patients with low peripheral blast (PB) burden. Most serious adverse events (SAEs) were infections and cytopenias that are considered to be consequences of AML and not drug related.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 01, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Acute Myeloid Leukemia, Actimab-a, Hum195-alpha, Cytogenetics
